TransCode Therapeutics Inc (NASDAQ:RNAZ) currently has a daily average trading volume of 1.42M but it saw 12463086 shares traded in last market. With a market cap of 7.91M USD, the company’s current market price of $11.37 came rising about 27.18 while comparing to the previous closing price of $8.94. In past 52 weeks, the stock remained buoying in the range of price level as high as $66.33 and as low as $2.66. In the recent trading on the day, stock has struck highest price mark of $10.68 while lowest mark touched by it was $14.2499.
Taking a look at 20-day trading activity of TransCode Therapeutics Inc (RNAZ) gives us an average price of $5.87, while its current price level is -82.86% below from 52-week high level whereas it is 327.44% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $6.41 while that of 200 days or SMA-200 reads an average of $18.02. A closer look into the stock’s movement over the week reveals that its volatility is standing at 39.68% during that period while stretching the period over a month that increases to 41.16%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 69.02 which implies that the stock is in neutral territory.
Over the week, RNAZ’s stock price is moving 41.24% up while it is 225.79% when we observe its performance for the past one month. Year-to-date it is 237.39% up and over the past year, the stock is showing a downside performance of -40.16%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -3.21 while estimate for next year EPS is -4.76. Moreover, analysts are in estimates of $300k for current-quarter revenue.
Currently, TransCode Therapeutics Inc’s total number of outstanding shares is 0.70M with 0.01% of that held by the insiders while 1.99% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -903.45% and return on equity (ROE) at -490.03%. Stock’s beta reads 0.99. Stock has a price to book (P/B) ratio of 3.60. Its return on asset (ROA) is -210.77% on average.
